|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Liver Cancer | |||||
| Metastatic Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Liver Neoplasms | |||||
| Neoplasm Metastasis | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Liver Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Neoplastic Processes | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| fludeoxyglucose F 18 | |||||
| gadopentetate dimeglumine | |||||
| computed tomography | |||||
| magnetic resonance imaging | |||||
| positron emission tomography | |||||
| radiofrequency ablation | |||||
| radionuclide imaging | |||||
| ultrasound imaging | |||||
| 5 | Sponsors listed in this trial | ||||
| NCI - Center for Cancer Research-Medical Oncology | |||||
| National Cancer Institute (NCI) | |||||